Shi‐Juan Mai

799 total citations
32 papers, 572 citations indexed

About

Shi‐Juan Mai is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shi‐Juan Mai has authored 32 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 12 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Shi‐Juan Mai's work include RNA modifications and cancer (7 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (4 papers). Shi‐Juan Mai is often cited by papers focused on RNA modifications and cancer (7 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (4 papers). Shi‐Juan Mai collaborates with scholars based in China, Hong Kong and United States. Shi‐Juan Mai's co-authors include Hui‐Yun Wang, Mei‐Yin Zhang, Yi‐Xin Zeng, Dan Xie, Ruiqi Wang, Hsiang‐Fu Kung, Yiji Liao, Xinge Zhao, Huizhong Zhang and Rong Deng and has published in prestigious journals such as Hepatology, Cancer Research and International Journal of Cancer.

In The Last Decade

Shi‐Juan Mai

30 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shi‐Juan Mai China 15 375 225 133 64 57 32 572
Timothy Wai Ho Shuen Singapore 12 350 0.9× 201 0.9× 135 1.0× 83 1.3× 77 1.4× 22 563
Chencheng Xie United States 11 342 0.9× 194 0.9× 125 0.9× 51 0.8× 44 0.8× 33 564
Ya‐Ching Lu Taiwan 12 466 1.2× 342 1.5× 144 1.1× 52 0.8× 50 0.9× 12 746
Yingxi Mo China 16 393 1.0× 280 1.2× 107 0.8× 59 0.9× 51 0.9× 36 580
Shikai Zhu China 14 341 0.9× 211 0.9× 159 1.2× 81 1.3× 59 1.0× 30 546
Huairui Yuan China 10 432 1.2× 159 0.7× 94 0.7× 62 1.0× 108 1.9× 14 600
Li-Xia Peng China 14 514 1.4× 331 1.5× 262 2.0× 59 0.9× 102 1.8× 15 766

Countries citing papers authored by Shi‐Juan Mai

Since Specialization
Citations

This map shows the geographic impact of Shi‐Juan Mai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐Juan Mai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐Juan Mai more than expected).

Fields of papers citing papers by Shi‐Juan Mai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shi‐Juan Mai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐Juan Mai. The network helps show where Shi‐Juan Mai may publish in the future.

Co-authorship network of co-authors of Shi‐Juan Mai

This figure shows the co-authorship network connecting the top 25 collaborators of Shi‐Juan Mai. A scholar is included among the top collaborators of Shi‐Juan Mai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shi‐Juan Mai. Shi‐Juan Mai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Di, Ji Liu, Qiannan Ren, et al.. (2024). CircATF6 inhibits hepatocellular carcinoma progression by suppressing calreticulin-mediated Wnt/β-catenin signaling pathway. Cellular Signalling. 122. 111298–111298. 1 indexed citations
2.
Shi, Lu, Chun Wu, Mei‐Yin Zhang, et al.. (2024). TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma. Medical Oncology. 41(3). 79–79. 1 indexed citations
3.
Ren, Qiannan, Danhui Huang, Yufeng Zhou, et al.. (2024). Two somatic mutations in the androgen receptor N-terminal domain are oncogenic drivers in hepatocellular carcinoma. Communications Biology. 7(1). 22–22.
4.
Sun, Chao‐Yue, Di Cao, Qiannan Ren, et al.. (2024). Cholesterol inhibition enhances antitumor response of gilteritinib in lung cancer cells. Cell Death and Disease. 15(9). 704–704. 6 indexed citations
5.
6.
Wu, Chun, Hongmu Li, Xuefei Liu, et al.. (2023). PD1hi CD200hi CD4+ exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial–mesenchymal transition in bladder cancer. Clinical and Translational Medicine. 13(6). e1303–e1303. 13 indexed citations
7.
Li, Hongmu, et al.. (2023). Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer. Frontiers in Bioscience-Landmark. 28(10). 243–243. 5 indexed citations
8.
9.
Sun, Chao‐Yue, Di Cao, Qiannan Ren, et al.. (2021). Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non–small-Cell Lung Cancer In Vivo and In Vitro. Frontiers in Pharmacology. 12. 684243–684243. 19 indexed citations
10.
Wang, Ruiqi, Xiaoran Long, Ningning Zhou, et al.. (2021). Lnc-GAN1 expression is associated with good survival and suppresses tumor progression by sponging mir-26a-5p to activate PTEN signaling in non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research. 40(1). 9–9. 25 indexed citations
11.
Wang, Ruiqi, Xiaoran Long, Chunlei Ge, et al.. (2020). Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China. Journal of Translational Medicine. 18(1). 320–320. 7 indexed citations
12.
Liu, Ji, Rui‐Hua Xu, Shi‐Juan Mai, et al.. (2020). LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. Theranostics. 10(17). 7527–7544. 31 indexed citations
13.
Shi, Lu, et al.. (2019). Identification of RRAS gene related to nasopharyngeal carcinoma based on pathway and network-based analyses. Translational Cancer Research. 8(2). 664–675. 7 indexed citations
14.
Mai, Shi‐Juan, et al.. (2019). Response to the hunt for the perfect biomarker in nasopharyngeal carcinoma—the RRAS “race” beyond Epstein-barr virus?. Translational Cancer Research. 8(6). 2506–2507. 1 indexed citations
15.
Zhao, Xinge, Jun Tang, Yi Wei, et al.. (2019). miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death and Disease. 10(7). 479–479. 87 indexed citations
16.
Wen, Wen, Shi‐Juan Mai, Huan‐Xin Lin, et al.. (2019). Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma. Journal of Translational Medicine. 17(1). 186–186. 27 indexed citations
17.
Jiang, Lili, Pei Dong, Zhiyuan Zhang, et al.. (2015). Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells. Cell Death and Disease. 6(2). e1660–e1660. 56 indexed citations
18.
Li, Yonghong, Yiji Liao, Shi‐Juan Mai, et al.. (2013). High Expression of H3K27me3 Is an Independent Predictor of Worse Outcome in Patients with Urothelial Carcinoma of Bladder Treated with Radical Cystectomy. BioMed Research International. 2013. 1–8. 18 indexed citations
19.
Liu, Yan‐Hui, Shi‐Juan Mai, Longjun He, et al.. (2009). Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. Journal of Gastroenterology and Hepatology. 25(6). 1123–1128. 24 indexed citations
20.
Li, Dajiang, Jin‐Xin Bei, Shi‐Juan Mai, et al.. (2009). The dominance of China 1 in the spectrum of Epstein–Barr virus strains from Cantonese patients with nasopharyngeal carcinoma. Journal of Medical Virology. 81(7). 1253–1260. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy Wai Ho Shuen Breakdown of academic impact, for papers by Chencheng Xie Breakdown of academic impact, for papers by Ya‐Ching Lu Breakdown of academic impact, for papers by Yingxi Mo Breakdown of academic impact, for papers by Shikai Zhu Breakdown of academic impact, for papers by Huairui Yuan Breakdown of academic impact, for papers by Li-Xia Peng
Rankless by CCL
2026